5-Methoxytryptophan alleviates atrial structural remodeling in ibrutinib-associated atrial fibrillation

Shuai, Wei; Peng, Bo; Zhu, Jun; Kong, Bin; Fu, Hui; Huang, He

doi:10.1016/j.heliyon.2023.e19501

Heliyon

2023

DOI: 10.1016/j.heliyon.2023.e19501

|View full text |Cite

5-Methoxytryptophan alleviates atrial structural remodeling in ibrutinib-associated atrial fibrillation

Wei Shuai,

Bo Peng,

Jun Zhu

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Predictive Value of 5-Methoxytryptophan on Long-Term Clinical Outcome after PCI in Patients with Acute Myocardial Infarction-a Prospective Cohort Study

Huang,

Wen,

Zhang

et al. 2024

J. of Cardiovasc. Trans. Res.

View full text Add to dashboard Cite

Background In recent years, 5-Methoxytryptophan (5-MTP) has been identified as an endothelial factor with vaso-protective and anti-inflammatory properties. Methods In this prospective cohort study, a total of 407 patients with acute myocardial infarction (AMI) who underwent percutaneous coronary intervention (PCI) successfully were enrolled. A 1-year follow-up Kaplan–Meier survival analysis was used for evaluating the correlation between 5-MTP and major adverse cardiovascular event (MACE) while Cox proportional-hazards regression was used to identify predictive values of 5-MTP on MACE after AMI. Results Increased 5-MTP level led to a significant downtrend in the incidence of MACE (All Log-rank p < 0.05). Thus, a high baseline 5-MTP could reduce the 1-year incidence of MACE (HR = 0.33, 95%Cl 0.17–0.64, p = 0.001) and heart failure (HF) (HR = 0.28, 95% Cl 0.13–0.62, p = 0.002). Subgroup analysis indicated the predictive value of 5-MTP was more significant in patients aged ≤ 65 years and those with higher baseline NT-proBNP, T2DM, STEMI, and baseline HF with preserved LVEF (HFpEF) characteristics. Conclusions Plasma 5-MTP is an independent and protective early biomarker for 1-year MACE and HF events in patients with AMI, especially in younger patients and those with T2DM, STEMI, and baseline HFpEF characteristics. Graphical Abstract

show abstract

Predictive Value of 5-Methoxytryptophan on Long-Term Clinical Outcome after PCI in Patients with Acute Myocardial Infarction-a Prospective Cohort Study

Huang,

Wen,

Zhang

et al. 2024

J. of Cardiovasc. Trans. Res.

View full text Add to dashboard Cite

show abstract

Cardiovascular toxicity in antitumor therapy: biological and therapeutic insights

Lin,

Ma,

Zhao

et al. 2024

Trends in Cancer

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

5-Methoxytryptophan alleviates atrial structural remodeling in ibrutinib-associated atrial fibrillation

Cited by 2 publications

References 28 publications

Predictive Value of 5-Methoxytryptophan on Long-Term Clinical Outcome after PCI in Patients with Acute Myocardial Infarction-a Prospective Cohort Study

Predictive Value of 5-Methoxytryptophan on Long-Term Clinical Outcome after PCI in Patients with Acute Myocardial Infarction-a Prospective Cohort Study

Cardiovascular toxicity in antitumor therapy: biological and therapeutic insights

Contact Info

Product

Resources

About